Found: 7
Select item for more details and to access through your institution.
TP53 is not a prognostic marker—clinical consequences of a generally disregarded fact.
- Published in:
- Annals of the New York Academy of Sciences, 2018, v. 1434, n. 1, p. 46, doi. 10.1111/nyas.13947
- By:
- Publication type:
- Article
Strategy for prevention of cancers of the esophagus.
- Published in:
- Annals of the New York Academy of Sciences, 2014, v. 1325, n. 1, p. 108, doi. 10.1111/nyas.12529
- By:
- Publication type:
- Article
TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 151, n. 3, p. 671, doi. 10.1007/s10549-015-3424-1
- By:
- Publication type:
- Article
Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development.
- Published in:
- Carcinogenesis, 2001, v. 22, n. 4, p. 665, doi. 10.1093/carcin/22.4.665
- By:
- Publication type:
- Article
Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients.
- Published in:
- International Journal of Cancer, 2006, v. 118, n. 6, p. 1465, doi. 10.1002/ijc.21524
- By:
- Publication type:
- Article
Two closely related forms of UDP-GlcNAc: α6-D-mannoside β1,2- N-acetylglucosaminyltransferase II occur in the clawed frog Xenopus laevis.
- Published in:
- Glycoconjugate Journal, 2002, v. 19, n. 3, p. 187, doi. 10.1023/A:1024201824354
- By:
- Publication type:
- Article
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected.
- Published in:
- European Surgery: ACA Acta Chirurgica Austriaca, 2018, v. 50, n. 4, p. 160, doi. 10.1007/s10353-018-0527-z
- By:
- Publication type:
- Article